Clinical Trials Logo

Hidradenitis Suppurativa clinical trials

View clinical trials related to Hidradenitis Suppurativa.

Filter by:

NCT ID: NCT06082323 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers

Start date: January 10, 2024
Phase: Phase 1
Study type: Interventional

LT-002-158 is a novel small molecule drug being developed as a potential therapy for the treatment of skin disorder disease includes Hidradenitis Suppurativa and Atopic Dermatitis.

NCT ID: NCT06072287 Recruiting - Obesity Clinical Trials

The Living With a Long-Term Condition Study

LTC
Start date: June 28, 2023
Phase:
Study type: Observational

Psychological distress (anxiety and depression) is common in and experienced differently by people living with long-term health conditions (LTCs). Being able to measure whether psychological distress is related to living with a LTC would allow researchers and clinicians to provide interventions specifically tailored to the challenges of living with a LTC and therefore provide the most appropriate support for these patients. Such a measure would also be useful in research to identify the presence of illness-related distress in different patient groups. This project will therefore create a new measure of illness-related distress that has applications for both research and clinical practice. This will involve the psychometric validation of the new illness-related distress measure to test how valid and reliable the measure is. The aim of the project is to provide initial validation of the Illness Related Distress Scale in a community sample, recruited through online platforms. The objective of the study is to gather initial validity and reliability data for the scale.

NCT ID: NCT06058520 Recruiting - Clinical trials for Hidradenitis Suppurativa

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Start date: October 1, 2023
Phase: Early Phase 1
Study type: Interventional

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There is only one currently FDA-approved treatment, adalimumab, but only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.

NCT ID: NCT06046729 Recruiting - Clinical trials for Hidradenitis Suppurativa

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Start date: October 23, 2023
Phase: Phase 2
Study type: Interventional

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

NCT ID: NCT06028230 Recruiting - Clinical trials for Hidradenitis Suppurativa

A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

ZEN
Start date: September 29, 2023
Phase: Phase 2
Study type: Interventional

This is a parallel, Phase 2, 2-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years. Study details include: - Screening period: up to 4 weeks (30 days) - Treatment duration: up to 16 weeks - Follow-up period: up to 4 weeks - Total study duration: up to 24 weeks - Number of visits: 14

NCT ID: NCT06015438 Recruiting - Clinical trials for Hidradenitis Suppurativa

Physical Activity in Hidradenitis Suppurativa (HS)

Start date: June 7, 2023
Phase: N/A
Study type: Interventional

The purpose of the study is to characterize the challenges to physical activity and exercise for HS patients and design an exercise program (EP) with evidence-based techniques and examine its outcome.

NCT ID: NCT05997277 Recruiting - Clinical trials for Hidradenitis Suppurativa

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Start date: November 30, 2023
Phase: Phase 2
Study type: Interventional

The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will be included in this single center, randomized, double-blind, parallel-group study. Dosage of deucravacitinib will be given according to the investigational regimen as follows: 6 mg po bid for 16 weeks. The study compromises a 4-week screening period, a 16-week study period, and a 4-week follow-up period. The follow-up period consists of a follow-up phone call 4 weeks after the last study drug dose.

NCT ID: NCT05994976 Recruiting - Atopic Dermatitis Clinical Trials

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Start date: October 17, 2023
Phase:
Study type: Observational

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

NCT ID: NCT05989945 Enrolling by invitation - Stroke Clinical Trials

HIDRAdenitis Suppurativa and HEART Disease

Start date: August 1, 2023
Phase:
Study type: Observational

In a prospective observational cohort study (n = 250) the investigators aim to assess the correlation between cardiac biomarkers, advanced echocardiography and HS severity and determine whether these are prognostic markers of heart disease in patients suffering from hidradenitis suppurativa (HS).

NCT ID: NCT05986825 Recruiting - Clinical trials for Hidradenitis Suppurativa

Validation of the French Version of the Score on Quality of Life (HiSQOL) in Hidradenitis Suppurativa (QUALIVER)

QUALIVER
Start date: August 29, 2023
Phase:
Study type: Observational

Validation of the French Version of the Score on Quality of Life in Hidradenitis Suppurativa. The French HiSQOL will be completed by 60 patients with hidradenitis suppurativa a first time, and a second time 1 week later.